# Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

> **NCT07548983** · PHASE1 · NOT_YET_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography Test
- **OTHER:** Electronic Health Record Review
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Mycophenolate Mofetil
- **OTHER:** Reduced-Intensity Transplant Conditioning Procedure
- **DRUG:** Ruxolitinib
- **OTHER:** Survey Administration
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT07548983
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-20
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-29
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07548983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07548983, "Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07548983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*